Andrew Ross Joins The Estée Lauder Companies to Lead Strategy and New Business Development
The Estée Lauder Companies Inc. (NYSE:EL) announced today the appointment of Andrew Ross to the role of Senior Vice President, Strategy and New Business Development, effective September 1, 2016. Mr. Ross succeeds Peter Jueptner, who, as previously announced, has been appointed President, Europe, the Middle East and Africa. Mr. Ross will join the Company’s Executive Leadership Team and report jointly to Fabrizio Freda, President and Chief Executive Officer, and Tracey T. Travis, Chief Financial Officer and Executive Vice President, Global Finance and Strategy.
In this important strategic role for the Company, Mr. Ross will lead the ongoing development and implementation of the Company’s strategy and 10-year Strategic Compass. Mr. Ross will also lead the Company’s mergers, acquisitions, licensing and alliance activities worldwide, identifying strategic opportunities to complement the Company’s brand portfolio and capabilities. Mr. Ross’s additional responsibilities will include creating alignment opportunities across the Company, generating breakthrough industry and global insights that impact the Company’s strategic direction and providing leadership and guidance for a variety of key strategic priorities. Central to Mr. Ross’s role will be mobilizing and tracking the execution of enterprise-wide projects to enable the Company to continue to achieve its long-term vision.
“Our sound corporate strategy has driven us to achieve seven years of consecutive growth,” said Mr. Freda. “Andrew’s widely-recognized industry leadership along with his depth of expertise in retail strategy, merchandising, format renewal and marketing will help us to continue to drive long-term profitable growth and remain a global leader in prestige beauty.”
For the past five years, Mr. Ross served as Executive Vice President and Chief Strategy Officer at ConAgra Foods, Inc., where he led the formulation of ConAgra’s corporate strategy, including oversight of their portfolio strategy, mergers and acquisitions. Previously, Mr. Ross was a Principal at McKinsey & Company, Inc., where he led the global retail and consumer goods pillar for nearly a decade. In this role, Mr. Ross was widely known for shaping global and national growth strategies for leading retail and consumer companies.
“Andrew brings a wealth of global strategic experience across the consumer goods, retail and consulting sectors. Andrew’s significant track record of shaping global growth, coupled with his proven ability to translate opportunities and challenges from ideas into actionable global strategies, positions him well to take on this very important role for our Company,” said Ms. Travis.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW and By Kilian.
The Estée Lauder Companies Inc.
Alexandra Trower, 212-572-4430
Dennis D’Andrea, 212-572-4384
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AURAK15.12.2018 11:51 | Pressemeddelelse
AURAK Gains SACSCOC Accreditation
KRAMER-LEVIN14.12.2018 18:44 | Pressemeddelelse
Lehman Brothers Treasury Announces Plans for Partial Wind-Down
MA-TAKEDA-PHARMACEUTICAL14.12.2018 18:02 | Pressemeddelelse
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
FL-POTNETWORK-HOLDINGS14.12.2018 16:44 | Pressemeddelelse
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules
HENLEY-&-PARTNERS14.12.2018 15:02 | Pressemeddelelse
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth
BOEHRINGER-INGELHEIM14.12.2018 10:09 | Pressemeddelelse
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum